The Catalyst

New White Paper: Recognizing Emerging Value in Oncology Treatments

Posted by Guest Contributor on May 27, 2015 at 12:46 PM

The American Society of Clinical Oncology (ASCO)’s Annual Conference is this week, and with a theme of “Illumination & Innovation: Transforming Data into Learning” we are excited to see the research being presented on ways to prevent, treat and cure cancer.  In the last several decades, our scientific understanding of cancer has grown immensely, and the U.S. cancer death rate has fallen 22 percent since its peak in 1991. Innovative cancer therapies have played a significant role in this decline; however, the most impactful changes to the care paradigm often emerge from existing therapies through their further evaluation in post-approval clinical studies and real-world data collection. Because accelerated approval is a key pathway to get drugs to patients who need them quickly, the full value of an oncology medicine is typically not known until well after a drug is available to patients.

In our new white paper released today,  “The Value of Innovation in Oncology: Recognizing Emerging Benefits Over Time,” we detail exactly how continued learning and accumulation of knowledge after approval often translates into increased clinical value for patients and the physicians who treat them.

Read More

Topics: Innovation, Oncology, ASCO, Healthy Outlook

How Manufacturing Advances Can Help Make Medicines More Effective

Posted by Tim McClung on May 26, 2015 at 4:21 PM

When we think about innovation in medicine development, we often don’t picture assembly lines or the industrial manufacturing methods that create the tablets, capsules, injectables or I.V. solutions which help patients live healthier, more productive lives. A new report from Deloitte analyzes recent trends in manufacturing technology innovation, providing new information on how new technologies over the past decade are positively impacting the ability of the biopharmaceutical industry to create new medicines and therapies. The making of medicines requires significant investment in building high-tech production facilities and equipment that has become central to the ability of manufacturers to align with advances in research and development.

Read More

Topics: Medicines in Development, Technology, Innovation, new medicines, Personalized Medicine

Medicare Monday: Happy Memorial Day!

Posted by Allyson Funk on May 25, 2015 at 9:00 AM

We wanted to take this #MedicareMonday to wish all of you a happy Memorial Day! But we didn’t want to leave you without some Medicare reading for your day by the pool or grilling on the patio, so here’s a look back on what we’ve covered over the last few months:

Read More

Topics: diabetes, Part D, Medicare, #MedicareMonday

Week in Review: The Latest from PhRMA

Posted by Priscilla VanderVeer on May 22, 2015 at 1:53 PM

High Out-of-Pocket Costs Hurt Patients: Even with health coverage, approximately 31 million Americans were considered “underinsured” last year due to high deductibles and increasing out-of-pocket costs, according to a new survey from the Commonwealth Fund. The study found that those with low incomes and/or health problems were at the greatest risk of being underinsured. Read more in a Catalyst post about the survey and check out for information on choosing a plan to meet your needs.

Read More

Topics: Personalized Medicine, Patents, IP, Medicare

Biopharmaceutical Companies Recognized as Meaningful Places to Work

Posted by John Tunnell on May 22, 2015 at 11:34 AM

Loretta was diagnosed with Stage 4 lung cancer 12 years ago - but thanks to medical breakthroughs and innovative medicines, she is living a happy, active life today.

Matt was given a five percent chance of living five more years when diagnosed with advanced non-small cell lung cancer - but advances in cancer research changed his prognosis and now he trains for half-marathons.

Read More

Topics: Rare Diseases, biopharmaceutical, healthcare professionals

ICYMI: New Commonwealth Fund Study Shows Health Insurance Does Not Always Translate to Affordable Care

Posted by Allyson Funk on May 21, 2015 at 5:50 PM

A new survey from the Commonwealth Fund found nearly a quarter of 19-to-64-year-old Americans with health insurance last year—approximately 31 million people—were considered “underinsured.” Meaning patients had health insurance, but their coverage did not always protect them from high medical bills and major financial issues. The culprit? Increasing deductibles and high out-of-pocket costs.

Key findings from the survey include:

  • Adults with low incomes or health problems are at greatest risk of underinsurance and have high rates of medical bill issues: 42 percent of those with incomes below the federal poverty level were underinsured.
  • Medical bill and debt problems have long-term financial consequences: Nearly half of survey respondents said they exhausted their savings to pay medical bills, nearly one quarter were dealing with collection agencies and 7 percent had to declare bankruptcy.
Read More

Topics: health insurance, coverage, ABCs of Coverage

340B Spotlight: New Charity Care Data Shows Most Hospitals with Contract Pharmacies Provide Little Charity Care

Posted by Karyn Schwartz on May 21, 2015 at 12:13 PM

New data raises even more questions about how hospitals are using for-profit pharmacies to expand a little known program called 340B. This program was designed to allow qualifying hospitals and clinics receiving certain federal grants to access deeply discounted pharmaceuticals so they can more easily provide medicines for their uninsured or vulnerable patients.

Unfortunately, there are not sufficient safeguards in place to ensure that hospitals qualifying for the program are true safety net hospitals providing a disproportionate share of charity care to low-income, uninsured patients.[1]

Now, new data shows the majority of hospitals that are aggressively expanding use of this program through for-profit pharmacies are actually providing below average levels of charity care.

Read More

Topics: 340B, HRSA, hospitals, 340B Spotlight

New Study Illustrates Biopharmaceutical Industry’s Commitment to Personalized Medicine

Posted by Gretta Stone on May 20, 2015 at 3:13 PM

Potential personalized medicines represent 42 percent of drugs in the pipeline. This new finding, from a survey by the Tufts Center for the Study for Drug Development (CSDD), is remarkably high, particularly given that about 15 years ago the science of genomic medicine was just developing and that number was virtually zero.

Until recently many believed that biopharmaceutical companies were resistant to personalized (or precision) medicine and were not performing research to advance the field. Critics often speculated that the science was too hard and companies would not consider developing medicines for such small patient populations.

Read More

Topics: Personalized Medicine, cancer, Tufts, Healthy Outlook

Patents: More Important to Biopharmaceutical Sector than Other Industries

Posted by Setareh Samii on May 18, 2015 at 3:23 PM

According to Abraham Lincoln, the patent system “secured to the inventor for a limited time exclusive use of his inventions, and thereby added the fuel of interest to the fire of genius in the discovery and productions of new and useful things.”

While this quote is from the mid-1800s, it is especially true today for the biopharmaceutical sector. It’s also timely as Congress is considering new legislation that would erode patent rights and potentially undermine industry’s ability to bring new treatments and cures to patients and grow the US economy.

Read More

Topics: R&D, Patents, IP, Congress

Medicare Monday: How Successful Negotiation Takes Place in Medicare

Posted by Allyson Funk on May 18, 2015 at 2:21 PM

#MedicareMonday is continuing to take a closer look at proposals that could hurt the success of Medicare Part D. This week we’re talking about proposals to repeal the non-interference clause in Medicare Part D.

What is non-interference?

From the beginning, the law creating Medicare Part D includes a provision called the non-interference clause; it prohibits the Secretary of Health and Human Services from interfering in the private price negotiations between Medicare Part D plans and drug manufacturers and pharmacies in the program, and prevents the Secretary from establishing a single formulary for the program.

Read More

Topics: Part D, CBO, Medicare, #MedicareMonday

Personalized Updates

Posts by Topic

see more